key: cord-1004997-am0wirio
authors: Gaietto, Kristina; Freeman, Megan Culler; DiCicco, Leigh Anne; Rauenswinter, Sherry; Squire, Joseph R.; Aldewereld, Zachary; Iagnemma, Jennifer; Campfield, Brian T.; Wolfson, David; Kazmerski, Traci M.; Forno, Erick
title: Asthma as a risk factor for hospitalization in children with COVID‐19: A nested case‐control study
date: 2021-11-24
journal: Pediatr Allergy Immunol
DOI: 10.1111/pai.13696
sha: 99dd02a761f848fa52fbd189c755f2e9ebebea36
doc_id: 1004997
cord_uid: am0wirio

BACKGROUND: Most pediatric studies of asthma and COVID‐19 to date have been ecological, which offer limited insight. We evaluated the association between asthma and COVID‐19 at an individual level. METHODS: Using data from prospective clinical registries, we conducted a nested case‐control study comparing three groups: children with COVID‐19 and underlying asthma (“A+C” cases); children with COVID‐19 without underlying disease (“C+” controls); and children with asthma without COVID‐19 (“A+” controls). RESULTS: The cohort included 142 A+C cases, 1110 C+ controls, and 140 A+ controls. A+C cases were more likely than C+ controls to present with dyspnea and wheezing, to receive pharmacologic treatment including systemic steroids (all p < .01), and to be hospitalized (4.9% vs. 1.7%, p = .01). In the adjusted analysis, A+C cases were nearly 4 times more likely to be hospitalized than C+ controls (adjusted OR = 3.95 [95%CI = 1.4–10.9]); however, length of stay and respiratory support level did not differ between groups. Among A+C cases, 8.5% presented with an asthma exacerbation and another 6.3% developed acute exacerbation symptoms shortly after testing positive for SARS‐CoV‐2. Compared to historic A+ controls, A+C cases had less severe asthma, were less likely to be on controller medications, and had better asthma symptom control (all p < .01). CONCLUSIONS: In our cohort, asthma was a risk factor for hospitalization in children with COVID‐19, but not for worse COVID‐19 outcomes. SARS‐CoV‐2 does not seem to be a strong trigger for pediatric asthma exacerbations. Asthma severity was not associated with higher risk of COVID‐19.

There have been conflicting reports on whether asthma increases COVID-19 risk or severity, [1] [2] [3] [4] [5] [6] with scarce data in children. 7 While the majority of COVID-19 cases have occurred in adults, 8 pediatric COVID-19 cases in the United States have been steadily increasing since July 2021. 9 The rise of the highly infectious Delta variant coincides with the return of millions of unimmunized students to inperson classrooms this fall with highly variable mitigation strategies, making it critically important that we better elucidate the impact of COVID-19 on children, particularly those with common chronic diseases such as asthma.

Most pediatric studies on COVID-19 and asthma to date have been epidemiological or ecological, which examine associations at a large scale but provide limited inferences into the individual characteristics driving the findings. For instance, there have been ecological reports describing reduced pediatric asthma exacerbations and morbidity during the pandemic, [10] [11] [12] [13] likely as a result of physical distancing, masks, and perhaps other factors such as decreases in air pollution. Yet, those have focused on the concurrent effects of the pandemic on population-level asthma morbidity and healthcare utilization, rather than the direct potential associations between asthma and incident COVID-19 characteristics in children.

In this study, we examined the association between asthma and COVID-19 in children using nested case-control analyses. We hypothesized that (1) there is an association between asthma and COVID-19 presentation and outcomes and (2) that asthma severity is correlated with COVID-19 risk.

The Western Pennsylvania COVID-19 Registry (WPACR) is a secure database established in March 2020 to record baseline characteristics, acute presentation, and initial outcomes of pediatric patients (ages 0-21 years) presenting with a SARS-CoV-2 infection to UPMC Children's Hospital of Pittsburgh (CHP, the largest pediatric referral center in the region) and Children's Community Pediatrics (CCP, the associated primary care network) 14 For this analysis, we extracted data from children with pre-existing asthma who presented with COVID-19 between March and December 2020 ("A+C" cases). As disease controls, we selected from the WPACR children without preexisting conditions who presented with COVID-19 ("C+" controls) during the same period, as well as non-overlapping children with asthma ("A+" controls) recruited to the CHP Asthma Registry during the same period the year prior to the pandemic (March to December 2019). The Asthma Registry includes children seen for asthma in the CHP Pulmonary or Allergy clinics, the Emergency Department, who are hospitalized for asthma, or who participate in asthma research studies at our center.

We have previously described details of the WPACR 14 in brief, we included subjects if they had a positive SARS-CoV-2 RT-PCR or if they met criteria for the multisystem inflammatory syndrome in chil- 16 scores for children 4-11 years old), lung function (FEV1 and FVC as percent of predicted [%pred], as well as FEV1/FVC ratio), and atopy biomarkers (total and specific IgE, allergy skin testing, and peripheral blood eosinophil counts). We defined asthma severity based on National Asthma Education and Prevention Program (NAEPP) guidelines 17 and poor control as an ACT or C-ACT ≤19. We evaluated asthma exacerbations in both the A+C and A+ groups from January 1, 2018, to December 31, 2019, to avoid any potential impact of the pandemic on asthma control, management, or healthcare utilization.

The WPACR and the CHP Asthma Registry are both approved by the Institutional Review Board at the University of Pittsburgh (protocols STUDY20110072 and STUDY19020359, respectively).

For the analysis of A+C cases vs C+ controls (i.e., the differences in COVID-19 between children with and without asthma), we compared initial symptoms at presentation, history of recent travel, and known exposures. Our primary outcomes of interest were hospitalization, hospital length of stay (LOS), PICU admission, and the maximal respiratory support required during hospitalization. For the analysis between A+C cases and A+ controls (i.e., to assess whether patients presenting with COVID-19 had more severe pre-existing asthma than expected from our usual hospital population), our primary variables were asthma severity and symptom control, and secondary characteristics were asthma exacerbations, lung function, and

Asthma severity was not associated with higher risk of COVID-19 in children, and SARS-CoV-2 was not a strong trigger for asthma exacerbations. Asthma was a risk factor for hospitalization in children with COVID-19, but not for worse COVID-19 outcomes. atopy biomarkers. We conducted bivariate analyses using 2-tailed t tests or Wilcoxon rank-sum (Mann-Whitney U) tests for continuous variables, and chi-squared or Fisher's exact tests for categorical variables. We conducted adjusted analyses using logistic regression for categorical variables (e.g., hospitalization), Poisson regression for count data (e.g., number of severe asthma exacerbations), or linear regression for continuous variables. We adjusted models for hospitalization for age, sex, and covariates that were significant in the bivariate analyses of asthma and hospitalization: race, zip code median household income, BMI, days from symptom onset to presentation, and non-asthma symptoms (fever, fatigue, and vomiting). In addition, we performed a sensitivity analysis using propensity score matching (PSM) to account for differences in relevant potential confounders such as age and race (see Online Supplement). We performed all analyses using STATA v16.1 (StataCorp, College Station, TX) or SAS v9.4 (SAS Institute, Cary, NC).

From March 11, 2020, to December 21, 2020, there were 1,802 cases with SARS-CoV-2 RT-PCR+in the WPACR (Figure 1 ). Of those, 142 had asthma and were extracted as A+C cases; and 1,110 had no reported pre-existing conditions and were selected as C+ controls. Distribution of COVID-19 cases over time showed a significant peak in the summer and a larger peak in the late fall/early winter ( Figure 2 ). We also extracted 140 non-overlapping asthma controls (A+ controls) recruited to the CHP Asthma Registry during the same period in 2019.

Baseline cohort characteristics are shown in Table 1 . A+C cases (COVID-19 with pre-existing asthma) were approximately 4 years older than both C+ and A+ controls (median ages 14.6, 12.0, and 10.2 years, respectively), but there were no differences in sex distributions between the three groups. Compared to children without asthma, those with asthma (with or without COVID-19) were more likely to be Black (A+C cases 25.4% and A+ controls 23.6%, vs. C+ controls 10.2%), had a higher BMI (median BMI percentiles 79.0 and 78.6, respectively, vs. 63.0), and were more likely to live in zip codes with lower household income (Table 1 ).

Altogether, 26 children (2.1%) in the WPCAR were hospitalized during the study period (Table S1 ), including 9 PICU admissions and no deaths. Compared to children with COVID-19 who were not hospitalized, hospitalized patients were more likely to have asthma (26.9% vs.

11.0%). They were also younger (median ages 7.4 vs. 12.6 years) and more likely to be Black (38.5% vs. 12.3%); to live in zip codes with lower median household income; to present with fever, fatigue, wheezing, dyspnea, chest pain, and/or vomiting; and to receive pharmacologic treatment (38.5% vs. 1.2%) (Table S1 ). There were no clear discernible hospitalization patterns over time ( Figure S1 ). PICU admissions were few but included 1/7 (14.3%) A+C cases and 8/19 (42.1%) C+ controls.

A+C cases were more likely than C+ controls to endorse recent travel; to present with wheezing, dyspnea, chest pain, and loss of taste; and to be hospitalized (4.9% vs. 1.7%) ( Table 2) . They were also more likely to receive pharmacologic treatment including albuterol (17.6% vs. 0.7%) and systemic steroids (8.5% vs. 0.8%). Among the 142 A+C cases, 12 (8.5%) had an asthma exacerbation upon initial presentation leading to SARS-CoV-2 testing, and 9 (6.3%) developed an asthma exacerbation shortly after they tested positive for COVID-19. In the remaining 118 cases, asthma was either solely a pre-existing condition with no active symptoms upon COVID-19 presentation (80.1%) or there was insufficient data to determine asthma symptoms (4.2%). A+C cases presenting with acute asthma symptoms were more likely to be hospitalized than those with no acute asthma symptoms ( In the multivariable analysis (Table 3) , asthma was a risk factor for hospitalization with COVID-19: After adjustment for age, sex, race, recent travel, and known exposure, A+C cases were nearly 4 times more likely to be hospitalized than C+ controls (aOR = 3.95

[95%CI = 1.4-10.9]; Table 3 Model 1). Results were similar after additionally adjusting for zip code household income, BMI percentile, and the number of days between symptom onset and presentation (Table 3 Model 2), or after adjusting for non-asthma symptoms that were associated with hospitalization (fever, fatigue, and vomiting; Table 3 Model 3). In our sensitivity analysis, PSM adequately balanced for relevant covariates ( Figure S2 , Table S2 ) and results were similar to those from the adjusted regression models, with odds ratios ranging from 3.38 to 4.08 (Table S3 ). Among hospitalized F I G U R E 1 Diagram of study cohort selection. A+C cases and C+ controls were recruited from March to December 2020. A+ controls were selected from patients recruited from March to December 2019. Data on asthma characteristics (for both A+C cases and A+ controls) were collected for 2018-2019 to avoid any potential impact of the pandemic on asthma control, management, or healthcare utilization patients, however, LOS and respiratory support level did not significantly differ by asthma status, although sample sizes were very small ( Table 2 ).

In our evaluation of whether children with asthma presenting with COVID-19 differ from children with asthma usually seen at our center ( We then evaluated the subgroup of cases and controls who had been previously seen at one of the asthma subspecialty clinics (17 A+C cases and 86 A+ controls seen in either Pulmonology or Allergy clinics; Table S4 ). In the analysis restricted to this subgroup, A+C cases and A+ controls were similar in most asthma characteristics, except for persistent differences in eosinophil counts and the proportion of patients with no atopic comorbidities.

Our study is one of the first individual-level, case-control studies on pediatric COVID-19 and asthma. To our knowledge, it is also one of the first studies to report the incidence of asthma exacerbations among children with asthma and acute SARS-CoV-2

infection.

Of the 1,802 patients in our pediatric COVID-19 registry during the study period, 142 (7.9%) had asthma. In our initial report over the first five months of the pandemic, asthma cases 29 More detailed, prospective, multi-center pediatric studies will be necessary to further examine this issue.

We found that SARS-CoV-2 does not seem to be a particularly strong trigger of asthma exacerbations, with only ~15% of children with asthma presenting with significant asthma symptoms during Note: Numbers shown are odds ratios (95% confidence intervals) for hospitalization. All models adjusted for age, sex, race, recent travel, and known exposure. Model 2 additionally adjusted for zip code's median household income, BMI percentile, and the time interval (days) between symptom onset and presentation; these were not included in Model 1 because of greater missingness (~30% were missing BMI or time interval data, thus N = 873). Model 3 additionally adjusted for non-asthma related symptoms that were significant in the unadjusted analysis (fever, fatigue, and vomiting; see Table S1 ).

*p < .05. **p < .01.

acute COVID-19. While we cannot rule out that some patients with asthma may have had exacerbations triggered by mild COVID-19

that were managed at home and who never sought medical attention, our estimates are consistent with a recent study of adolescents and adults with COVID-19 that similarly reported that only 13% of patients with asthma had acute wheezing. 30 As expected, children with asthma were more likely to receive systemic steroids as part of their management, and those presenting with acute asthma TA B L E 4 Asthma characteristics in COVID-19 cases (A+C) and asthma (A+) controls symptoms were more likely to be hospitalized-again suggesting that at least some of those admissions may have been due to asthma rather than COVID-19 severity.

In our analysis of cases vs historic asthma controls, we found that asthma severity was not associated with higher risk of SARS-CoV-2 infection. Due to the nature of our registries, we were unable to compare these patients to children with asthma managed by community providers (i.e., without subspecialty referral or recent admissions to our hospital). However, our findings suggest that children with asthma and COVID-19 were at least not as severe as those who would have been usually referred to subspecialty asthma care at our center. When we restricted our analyses to children with asthma who had been followed by a specialty clinic in the years prior to the pandemic, there was no significant difference in severity or symptoms compared to controls. While the sample size for this subgroup analysis was small, it again suggests that asthma severity was no different in children with COVID-19 than what we would have expected from the population our center usually serves.

Several factors contribute to a complex relationship between asthma and COVID-19. Obesity is a risk factor for asthma 31 and has been identified as a risk factor for COVID-19 infection and worse outcomes. 32 In our analysis, children with asthma had higher BMI, but this did not alter the association between asthma and hospitalization. Likewise, African American children in our cohort were more likely to have asthma and to be hospitalized for COVID-19, consistent with prior studies identifying racial disparities in asthma and severe COVID-19. [33] [34] [35] We also found that children with asthma presenting with COVID-19 had lower eosinophil counts and fewer atopic comorbidities than asthma controls. Eosinopenia has been associated with worse outcomes and mortality in adult COVID-19. 36, 37 Eosinophils play an important role in the immune response to respiratory viruses; atopic patients with higher eosinophil counts may be somewhat "protected" from SARS-CoV-2 infection, 38 and A+C cases with relatively lower counts may have thus been more susceptible.

Gene expression of ACE2, which plays a crucial role in SARS-CoV-2 cell entry, is lower in asthma and in younger ages, 39 There are several key strengths to this study. It is one of the first studies to compare COVID-19 presentation and outcomes between children with and without asthma using individual-level characteristics rather than ecological data and is likely the first such study in a cohort from the United States. There has been a significant knowledge gap regarding COVID-19 outcomes of children with underlying pulmonary diseases; this study starts to fill some of these gaps, which is of utmost importance for counseling families of children with asthma. Data for this study are based on registries in which information is manually abstracted from the EHR by a multidisciplinary team who is involved in the care of patients with COVID-19, providing more detailed, complete, and accurate information than reports based on diagnostic or billing codes. Furthermore, all asthma information for both cases and historic controls was abstracted by a single asthma provider, eliminating concerns for inter-rater bias.

Finally, given our sample size, we were able to evaluate subgroup characteristics, such as those patients with asthma referred to subspecialty care at our center.

Our study also has several limitations. Given the nature of the pandemic, follow-up duration has been short, precluding the ability to track long-term outcomes. However, it seems unlikely that asthma would have a lasting impact on COVID-19 outcomes, given the generally mild courses of the children in this study. Yet, future studies should also focus on long-term consequences such as changes in lung function or asthma severity and control in children who recovered from acute COVID-19. Another limitation is the small number of hospitalized patients in this study; it is unclear whether this is secondary to regional variation in severity or management, possibly due to local variants, or whether the low proportion of hospitalized children is secondary to our ability to include even mild and asymptomatic cases in the registry. It will be crucial to analyze multi-center data to evaluate whether findings vary across different settings. In addition, our analysis was limited to data from the EHR, and thus, other relevant covariates were not included. Moreover, the current study period preceded the emergence of the Delta variant of the virus; our registry is ongoing, and we plan to analyze potential differences as we see the already surging wave of pediatric cases across the country.

In summary, we found that asthma severity does not seem to be associated with increased risk of SARS-CoV-2 infection in children. Pre-existing asthma did increase the risk of hospitalization for COVID-19 in our population, but hospital LOS, need for respiratory support, and disposition did not differ from children without asthma.

Furthermore, SARS-CoV-2 infection was not commonly a trigger for asthma exacerbations, but children presenting with symptoms of an asthma exacerbation were more likely to be admitted. With the advent of the Delta variant and current rise in COVID-19 cases, it will be important to conduct multi-center, individual-level, case-control, or cohort studies of COVID-19 and asthma to better understand this evolving disease and its impact on children with asthma.

The authors declare no conflicts of interest related to the current work. 

The peer review history for this article is available at https://publo ns.com/publo n/10.1111/pai.13696.

Erick Forno https://orcid.org/0000-0001-6497-9885

Does asthma affect morbidity or severity of COVID-19?

Asthma and the coronavirus disease 2019 pandemic: a literature review

Allergic disorders and susceptibility to and severity of COVID-19: a nationwide cohort study

Factors associated with COVID-19-related death using OpenSAFELY

Association between asthma and clinical mortality/morbidity in COVID-19 patients using clinical epidemiologic data from Korean disease control and prevention

Asthma in COVID-19 hospitalizations: an overestimated risk factor?

Asthma and COVID-19 in children: a systematic review and call for data

COVID-19 Data Tracker

State-Level Data Report

Initial effects of the COVID-19 pandemic on pediatric asthma emergency department utilization

Impact of the COVID-19 Pandemic on Pediatric Emergency Department Use for Asthma

Reduced pediatric urgent asthma utilization and exacerbations during the COVID-19 pandemic

Unexpected decline in pediatric asthma morbidity during the coronavirus pandemic

A comprehensive clinical description of pediatric SARS-CoV-2 infection in Western Pennsylvania

Development of the asthma control test: a survey for assessing asthma control

Development and crosssectional validation of the childhood asthma control test

2020 focused updates to the asthma management guidelines: a report from the national asthma education and prevention program coordinating committee expert panel working group

Most Recent Asthma Data

Allegheny County Asthma Task Force Report

Allegheny County Health Department

Prevalence of asthma in hospitalized and non-hospitalized children with COVID-19

Clinical characteristics of 182 pediatric COVID-19 patients with different severities and allergic status

Severe coronavirus disease-2019 in children and young adults in the Washington, DC, metropolitan region

Children and adolescents with allergy and/or asthma seem to be protected from coronavirus disease 2019

Clinical characteristics and outcomes of hospitalized and critically ill children and adolescents with coronavirus disease 2019 at a tertiary care medical center

Clinical manifestations of children and adolescents with Covid-19: report of the first 115 cases from Sabara Hospital Infantil

Evaluation of the Clinical and Laboratory Findings of Asthmatic Children with SARS-CoV-2 Infection

Risk Factors for Severe COVID-19 in Children

COVID-19 in children with underlying chronic respiratory diseases: survey results from 174 centres

Outcomes among patients with COVID-19 and asthma: a systematic review and meta-analysis

Symptoms in patients with asthma infected by SARS-CoV-2

Obesity and asthma

Obesity as a risk factor for severe COVID-19: summary of the best evidence and implications for health care

COVID-19 and Racial/Ethnic Disparities

Racial and ethnic disparities in COVID-19-related infections, hospitalizations, and deaths: a systematic review

Racial disparities in incidence and outcomes among patients with COVID-19

Clinical features of 85 fatal cases of COVID-19 from Wuhan. A retrospective observational study

Behavior of eosinophil counts in recovered and deceased COVID-19 patients over the course of the disease

Eosinophil responses during COVID-19 infections and coronavirus vaccination

Nasal gene expression of angiotensin-converting enzyme 2 in children and adults

Association of respiratory allergy, asthma, and expression of the SARS-CoV-2 receptor ACE2

Inhaled corticosteroids downregulate the SARS-CoV-2 receptor ACE2 in COPD through suppression of type I interferon

Risk of COVID-19-related death among patients with chronic obstructive pulmonary disease or asthma prescribed inhaled corticosteroids: an observational cohort study using the OpenSAFELY platform

Additional supporting information may be found in the online version of the article at the publisher's website.